In just three years, CRISPR gene editing has hurtled to the forefront of biological science – with vast potential in agribusiness, human health, and industrial biotechnology. And unlike many nascent biotechs, which take years to attract significant funding, CRISPR has already attracted a lot of commercial interest. 2015 was a banner year for the technology. One could wager that once this patent nonsense is behind us, CRISPR will accelerate forward at breakneck pace.
The Broad Institute has a comprehensive timeline of CRISPR’s scientific development. Scientific American just published a story that details CRISPR’s commercial timeline. Here it is, sequentially:
- Novartis signs two deals with Intellia Therapeutics and Caribou Biosciences to engineer immune cells and blood stem cells, meant for drug discovery research.
- AstraZeneca signs four deals with the Wellcome Trust Sanger Institute, the Innovative Genomics Initiative, the Broad and Whitehead Institutes in Massachusetts, and Thermo Fisher Scientific. It’s meant for preclinical validation of new drug targets.
- Juno Therapeutics and Editas Medicine collaborate on next-gen CAR-T and TCR Cell therapies.
- Bill Gates and other top VCs invest $120 million into Editas Medicine.
- Vertex Pharmaceuticals and CRISPR Therapeutics sign a deal worth up to $2.6 billion.
- Bayer and CRISPR Therapeutics team up in a $335 million gene editing pact to develop new therapies for blood disorders, blindness and congenital heart disease.
- Editas Medicine files for a $100 million IPO